Will Oxford Immunotec Global PLC (OXFD) Short Squeeze Soon? The Stock Formed a Bearish Wedge Down Chart Pattern

December 7, 2017 - By Louis Casey

Investors sentiment decreased to 1.27 in 2017 Q2. Its down 0.56, from 1.83 in 2017Q1. It fall, as 10 investors sold Oxford Immunotec Global PLC shares while 20 reduced holdings. 8 funds opened positions while 30 raised stakes. 19.91 million shares or 1.07% more from 19.70 million shares in 2017Q1 were reported.
Alyeska Invest Grp Inc Lp accumulated 941,625 shares. Prelude Mngmt Ltd Co holds 0.04% or 23,960 shares in its portfolio. 194 were reported by National Bank Of America De. United Svcs Automobile Association reported 0.01% stake. Keybank Association Oh has 0.01% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 55,262 shares. Vanguard Group Incorporated Incorporated holds 69,043 shares. Deerfield Management Communications holds 0.85% or 945,710 shares in its portfolio. Rhumbline Advisers reported 24,500 shares. National Bank & Trust Of New York Mellon Corp owns 62,566 shares. Glenmede Comm Na has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). 423,831 are held by Wasatch Inc. Schwab Charles Investment Mgmt Incorporated stated it has 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Ny State Common Retirement Fund invested in 22,300 shares. Tiverton Asset Management Lc has invested 0.18% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Manufacturers Life Communications The accumulated 18,631 shares.

Since June 15, 2017, it had 0 insider purchases, and 1 insider sale for $61,305 activity.

The stock of Oxford Immunotec Global PLC (OXFD) formed a down wedge with $13.36 target or 4.00 % below today’s $13.92 share price. The 6 months wedge indicates high risk for the $357.12M company. If the $13.36 price target is reached, the company will be worth $14.28 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 1.90% or $0.27 during the last trading session, reaching $13.92. About 105,114 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since December 8, 2016 and is uptrending. It has outperformed by 37.56% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.34 earnings per share, down 54.55 % or $0.12 from last year’s $-0.22 per share. After $-0.24 actual earnings per share reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 41.67 % negative EPS growth.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 8 analyst reports since July 19, 2017 according to SRatingsIntel. The company was maintained on Tuesday, October 31 by Cowen & Co. The company was maintained on Tuesday, October 31 by Robert W. Baird. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) has “Buy” rating given on Wednesday, August 16 by Cowen & Co. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) on Wednesday, July 19 with “Buy” rating. Robert W. Baird maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Thursday, October 19. Robert W. Baird has “Buy” rating and $22.0 target. The firm earned “Buy” rating on Wednesday, September 27 by Cowen & Co. BTIG Research initiated Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Thursday, September 28. BTIG Research has “Buy” rating and $21.0 target.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Globenewswire.com which released: “Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer” on July 24, 2017, also Seekingalpha.com with their article: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q2 2017 Results …” published on August 01, 2017, Seekingalpha.com published: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q3 2017 Results …” on October 31, 2017. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Globenewswire.com and their article: “Oxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference” published on November 10, 2017 as well as Globenewswire.com‘s news article titled: “Oxford Immunotec Announces National Reimbursement for the T-SPOTĀ®.TB Test in …” with publication date: June 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.